Abstract | OBJECTIVE: To determine the application of serum thymidine kinase 1 (STK1) in general health screening for early detection of premalignant/early malignant tumors. METHODS: A cross sectional study was carried out in 26 055 health screenings from 8 centers of Changsha in 2011. The concentration of STK1 was determined by a sensitive chemiluminescent dot blot ECL assay. RESULTS: In the elevated STK1 group 60.35% showed diseases with a higher risk of premalignant/ early cancerous progression. The positive rate of elevated STK1 (>2.0 pmol/L) was 2.61%. There was a significantly higher rate with moderate/severe type of hyperplasia of breasts and prostate with elevated STK1 than people with normal STK1 values. CONCLUSION: STK1 may be a reliable marker for risk assessment of premalignant/early malignant tumors.
|
Authors | Xia Cao, Yaqin Wang, Pingting Yang, Hui Zhou, Chang Liu, Zhiheng Chen |
Journal | Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
(Zhong Nan Da Xue Xue Bao Yi Xue Ban)
Vol. 39
Issue 10
Pg. 1029-34
(Oct 2014)
ISSN: 1672-7347 [Print] China |
PMID | 25355255
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Biomarkers, Tumor
- Thymidine Kinase
- thymidine kinase 1
|
Topics |
- Biomarkers, Tumor
(blood)
- Breast
(pathology)
- Cross-Sectional Studies
- Early Detection of Cancer
- Female
- Humans
- Hyperplasia
- Male
- Neoplasms
(diagnosis)
- Precancerous Conditions
(diagnosis)
- Prostate
(pathology)
- Thymidine Kinase
(blood)
|